A HEAD-TO-HEAD COMPARISON OF IXEKIZUMAB AND ADALIMUMAB IN BIOLOGIC-NAiVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES FROM A RANDOMIZED, OPEN-LABEL, BLINDED ASSESSOR STUDY

Authors
Publication date
1 April 2020
Publisher
'Ovid Technologies (Wolters Kluwer Health)'

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    University of Queensland eSpace

    redirect
    oaioai:espace.library.uq.edu.au:U...
    Last time updated on 04/09/2020